1) This pilot trial demonstrated utility of oral propranolol in management of epistaxis in HHT 2) Propranolol was effective in reducing the severity and frequency of nosebleeds in HHT, as measured by the epistaxis severity scale, and this improvement is mirrored by an improvement in global quality of life 3) Adverse effects were experienced by a minority of patients, with the most significant event being pitting oedema 4) Following cessation of treatment, patients demonstrated a trend of regression with worsening of epistaxis scores 5) Further investigation is justified by its favourable effects, wide availability, and minimal side effect profile